Peptide Knowledge Base · Cognition
PE-22-28: what it is, what the evidence says, and its real status
A spadin-derived peptide that blocks the TREK-1 channel, studied preclinically for fast-acting antidepressant effects.
Short version: a preclinical mood peptide built around a fast-antidepressant mechanism (TREK-1 blockade). Interesting target, no human data. Education only.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Research-only · Education only.
Not offered, education only. PE-22-28 is a preclinical mood-targeting peptide with no human data. Not FDA-approved, not available, and not a substitute for mental-health care.
How does PE-22-28 work?
A spadin-derived peptide that blocks the TREK-1 potassium channel, a target linked to fast-acting antidepressant effects in animal models.
What it does — and what it does not do
What it does: Showed antidepressant-like effects in animal studies.
What it does not do: It has no human data, is not approved, and is not a treatment for depression or any mood condition.
How honest is the evidence?
Evidence grade D — preclinical only; no human data. Read our grading methodology for what each grade means.
What we still don't know: No human safety or efficacy data; durability of the antidepressant effect is unknown.
WADA status: Not prohibited.
How it is taken
Not offered; education only.
Who should not take it
No human characterization; not a substitute for evaluation/treatment of a mood disorder.
Sources
Spadin / PE-22-28 TREK-1 antidepressant preclinical literature
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.